Literature DB >> 12970441

Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7.

Wanxia He1, Doug Staples, Clark Smith, Chris Fisher.   

Abstract

Addition of human papillomavirus (HPV) E7 CDK2/cyclin A or CDK2/cyclin E, purified from either insect cells or bacteria, dramatically upregulates histone H1 kinase activity. Activation is substrate specific, with a smaller effect noted for retinoblastoma protein (Rb). The CDK2 stimulatory activity is equivalent in high-risk (HPV type 16 [HPV16] and HPV31) and low-risk (HPV6b) E7. Mutational analyses of HPV16 E7 indicate that the major activity resides in amino acids 9 to 38, spanning CR1 and CR2, and does not require casein kinase II or Rb-binding domain functions. Synthetic peptides spanning HPV16 amino acid residues 9 to 38 also activate CDK2. Peptides containing this sequence that carry biotin on the carboxy terminus, as well as a photoactivated cross-linking group (benzophenone), also activate the complex and covalently associate with the CDK2/cyclin A complex in a specific manner requiring UV. Cross-linking studies that use protein monomers detect association of the E7 peptides with cyclin A but not CDK2. Together, our results indicate a novel mechanism whereby E7 promotes HPV replication by directly altering CDK2 activity and substrate specificity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970441      PMCID: PMC228519          DOI: 10.1128/jvi.77.19.10566-10574.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators.

Authors:  L Morris; K E Allen; N B La Thangue
Journal:  Nat Cell Biol       Date:  2000-04       Impact factor: 28.824

Review 2.  The role of histone H1 in chromatin condensation and transcriptional repression.

Authors:  M Buttinelli; G Panetta; D Rhodes; A Travers
Journal:  Genetica       Date:  1999       Impact factor: 1.082

3.  Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity.

Authors:  P Massimi; D Pim; L Banks
Journal:  J Gen Virol       Date:  1997-10       Impact factor: 3.891

4.  HPV-16 E7 protein bypasses keratinocyte growth inhibition by serum and calcium.

Authors:  X F Pei; L Sherman; Y H Sun; R Schlegel
Journal:  Carcinogenesis       Date:  1998-08       Impact factor: 4.944

Review 5.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

6.  Association of the human papillomavirus type 11 E1 protein with histone H1.

Authors:  C S Swindle; J A Engler
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein.

Authors:  S Caldeira; E M de Villiers; M Tommasino
Journal:  Oncogene       Date:  2000-02-10       Impact factor: 9.867

8.  The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle.

Authors:  E R Flores; B L Allen-Hoffmann; D Lee; P F Lambert
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium.

Authors:  M N Ruesch; L A Laimins
Journal:  Virology       Date:  1998-10-10       Impact factor: 3.616

10.  Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes.

Authors:  R J Jewers; P Hildebrandt; J W Ludlow; B Kell; D J McCance
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more
  28 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Role of Cdk1 in DNA damage-induced G1 checkpoint abrogation by the human papillomavirus E7 oncogene.

Authors:  Xueli Fan; Jason J Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis.

Authors:  Scott Balsitis; Fred Dick; Nicholas Dyson; Paul F Lambert
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 4.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

Review 5.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

6.  HPV episome levels are potently decreased by pyrrole-imidazole polyamides.

Authors:  Terri G Edwards; Kevin J Koeller; Urszula Slomczynska; Kam Fok; Michael Helmus; James K Bashkin; Chris Fisher
Journal:  Antiviral Res       Date:  2011-06-02       Impact factor: 5.970

Review 7.  Impact of Replication Stress in Human Papillomavirus Pathogenesis.

Authors:  Cary A Moody
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 8.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

9.  The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints.

Authors:  Weifang Zhang; Jing Li; Sriramana Kanginakudru; Weiming Zhao; Xiuping Yu; Jason J Chen
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

10.  Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin.

Authors:  Christine L Nguyen; Catherine Eichwald; Max L Nibert; Karl Münger
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.